<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35437103</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>20</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>29</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1475-6374</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>37</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>Journal of enzyme inhibition and medicinal chemistry</Title>
          <ISOAbbreviation>J Enzyme Inhib Med Chem</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Interactions of 2,6-substituted purines with purine nucleoside phosphorylase from <i>Helicobacter pylori</i> in solution and in the crystal, and the effects of these compounds on cell cultures of this bacterium.</ArticleTitle>
        <Pagination>
          <StartPage>1083</StartPage>
          <EndPage>1097</EndPage>
          <MedlinePgn>1083-1097</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/14756366.2022.2061965</ELocationID>
        <Abstract>
          <AbstractText><i>Helicobacter pylori</i> represents a global health threat with around 50% of the world population infected. Due to the increasing number of antibiotic-resistant strains, new strategies for eradication of <i>H. pylori</i> are needed. In this study, we suggest purine nucleoside phosphorylase (PNP) as a possible new drug target, by characterising its interactions with 2- and/or 6-substituted purines as well as the effect of these compounds on bacterial growth. Inhibition constants are in the micromolar range, the lowest being that of 6-benzylthio-2-chloropurine. This compound also inhibits <i>H. pylori</i> 26695 growth at the lowest concentration. X-ray structures of the complexes of PNP with the investigated compounds allowed the identification of interactions of inhibitors in the enzyme's base-binding site and the suggestion of structures that could bind to the enzyme more tightly. Our findings prove the potential of PNP inhibitors in the design of drugs against <i>H. pylori</i>.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Narczyk</LastName>
            <ForeName>Marta</ForeName>
            <Initials>M</Initials>
            <Identifier Source="ORCID">0000-0002-7844-7262</Identifier>
            <AffiliationInfo>
              <Affiliation>Division of Biophysics, Institute of Experimental Physics, Faculty of Physics, University of Warsaw, Warsaw, Poland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wojtyś</LastName>
            <ForeName>Marta Ilona</ForeName>
            <Initials>MI</Initials>
            <Identifier Source="ORCID">0000-0003-3850-7598</Identifier>
            <AffiliationInfo>
              <Affiliation>Division of Biophysics, Institute of Experimental Physics, Faculty of Physics, University of Warsaw, Warsaw, Poland.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Bacterial Genetics, Institute of Microbiology, Faculty of Biology, University of Warsaw, Warsaw, Poland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Leščić Ašler</LastName>
            <ForeName>Ivana</ForeName>
            <Initials>I</Initials>
            <Identifier Source="ORCID">0000-0002-0826-7493</Identifier>
            <AffiliationInfo>
              <Affiliation>Division of Physical Chemistry, Ruđer Bošković Institute, Zagreb, Croatia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Žinić</LastName>
            <ForeName>Biserka</ForeName>
            <Initials>B</Initials>
            <Identifier Source="ORCID">0000-0002-1536-7142</Identifier>
            <AffiliationInfo>
              <Affiliation>Division of Organic Chemistry and Biochemistry, Ruđer Bošković Institute, Zagreb, Croatia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Luić</LastName>
            <ForeName>Marija</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Physical Chemistry, Ruđer Bošković Institute, Zagreb, Croatia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jagusztyn-Krynicka</LastName>
            <ForeName>Elżbieta Katarzyna</ForeName>
            <Initials>EK</Initials>
            <Identifier Source="ORCID">0000-0003-0484-9290</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Bacterial Genetics, Institute of Microbiology, Faculty of Biology, University of Warsaw, Warsaw, Poland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Štefanić</LastName>
            <ForeName>Zoran</ForeName>
            <Initials>Z</Initials>
            <Identifier Source="ORCID">0000-0002-3486-4291</Identifier>
            <AffiliationInfo>
              <Affiliation>Division of Physical Chemistry, Ruđer Bošković Institute, Zagreb, Croatia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bzowska</LastName>
            <ForeName>Agnieszka</ForeName>
            <Initials>A</Initials>
            <Identifier Source="ORCID">0000-0002-3976-429X</Identifier>
            <AffiliationInfo>
              <Affiliation>Division of Biophysics, Institute of Experimental Physics, Faculty of Physics, University of Warsaw, Warsaw, Poland.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>J Enzyme Inhib Med Chem</MedlineTA>
        <NlmUniqueID>101150203</NlmUniqueID>
        <ISSNLinking>1475-6366</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011687">Purines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.4.2.1</RegistryNumber>
          <NameOfSubstance UI="D011683">Purine-Nucleoside Phosphorylase</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D001665" MajorTopicYN="N">Binding Sites</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018929" MajorTopicYN="N">Cell Culture Techniques</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016480" MajorTopicYN="Y">Helicobacter pylori</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011683" MajorTopicYN="Y">Purine-Nucleoside Phosphorylase</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011687" MajorTopicYN="N">Purines</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Helicobacter pylori</Keyword>
        <Keyword MajorTopicYN="N">X-ray structure</Keyword>
        <Keyword MajorTopicYN="N">minimal inhibitory concentration</Keyword>
        <Keyword MajorTopicYN="N">purine nucleoside phosphorylase</Keyword>
        <Keyword MajorTopicYN="N">substituted purines</Keyword>
      </KeywordList>
      <CoiStatement>No potential conflict of interest was reported by the author(s).</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>19</Day>
          <Hour>5</Hour>
          <Minute>42</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35437103</ArticleId>
        <ArticleId IdType="pmc">PMC9037209</ArticleId>
        <ArticleId IdType="doi">10.1080/14756366.2022.2061965</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Marshall BJ, Warren JR.. 
Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet
1984;1:1311–5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6145023</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Makola D, Peura DA, Crowe SE.. 
Helicobacter pylori infection and related gastrointestinal diseases. J Clin Gastroenterol
2007;41:548–58.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17577110</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Robinson K, Atherton JC.. 
The spectrum of Helicobacter-mediated diseases. Annu Rev Pathol Mech Dis
2021;16:123–44.</Citation>
        </Reference>
        <Reference>
          <Citation>Falco MDE, Lucariello A, Iaquinto S, et al.. 
Molecular mechanisms of Helicobacter pylori pathogenesis. J Cell Physiol
2015;230:1702–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25639461</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cover TL.
Helicobacter pylori diversity and gastric cancer risk. mBio
2016;7:1–9.</Citation>
        </Reference>
        <Reference>
          <Citation>Schistosomes, liver flukes and Helicobacter pylori. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Lyon, 7–14 June 1994. IARC Monogr Eval Carcinog Risks Hum
1994;61:1–241.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7681621</ArticleId>
            <ArticleId IdType="pubmed">7715068</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Georgopoulos S, Papastergiou V.. 
An update on current and advancing pharmacotherapy options for the treatment of H. pylori infection. Expert Opin Pharmacother
2021;22:729–41.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33131337</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De Freitas LC.
WHO (2017) Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. Cad Pesqui
2013;43:348–65.</Citation>
        </Reference>
        <Reference>
          <Citation>Roszczenko-Jasińska P, Wojtyś MI, Jagusztyn-Krynicka EK.. 
Helicobacter pylori treatment in the post-antibiotics era-searching for new drug targets. Appl Microbiol Biotechnol
2020;104:9891–905.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7666284</ArticleId>
            <ArticleId IdType="pubmed">33052519</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Campestre C, De Luca V, Carradori S, et al.. 
Carbonic anhydrases: new perspectives on protein functional role and inhibition in Helicobacter pylori. Front Microbiol
2021;12:1–12.</Citation>
        </Reference>
        <Reference>
          <Citation>Ullman B, Carter D.. 
Hypoxanthine-guanine phosphoribosyltransferase as a therapeutic target in protozoal infections. Infect Agents Dis
1995;4:29–40.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7728354</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>El Kouni MH.
Potential chemotherapeutic targets in the purine metabolism of parasites. Pharmacol Ther
2003;99:283–309.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12951162</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>de Koning HP, Bridges DJ, Burchmore RJS.. 
Purine and pyrimidine transport in pathogenic protozoa: from biology to therapy. FEMS Microbiol Rev
2005;29:987–1020.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16040150</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hyde JE.
Fine targeting of purine salvage in cryptosporidium parasites. Trends Parasitol
2008;24:336–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18586557</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Berg M, Van der Veken P, Goeminne A, et al.. 
Inhibitors of the purine salvage pathway: a valuable approach for antiprotozoal chemotherapy?
Curr Med Chem
2010;17:2456–81.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20491648</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Evans GB, Tyler PC, Schramm VL.. 
Immucillins in infectious diseases. ACS Infect Dis
2018;4:107–17.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6034505</ArticleId>
            <ArticleId IdType="pubmed">29151351</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liechti G, Goldberg JB.. 
Helicobacter pylori relies primarily on the purine salvage pathway for purine nucleotide biosynthesis. J Bacteriol
2012;194:839–54.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3272961</ArticleId>
            <ArticleId IdType="pubmed">22194455</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Il’icheva IA, Polyakov KM, Mikhailov SN.. 
Strained conformations of nucleosides in active sites of nucleoside phosphorylases. Biomolecules
2020;10:552.</Citation>
        </Reference>
        <Reference>
          <Citation>Koellner G, Luić M, Shugar D, et al.. 
Crystal structure of the ternary complex of E. coli purine nucleoside phosphorylase with formycin B, a structural analogue of the substrate inosine, and phosphate (sulphate) at 2.1 A resolution. J Mol Biol
1998;280:153–66.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9653038</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Narczyk M, Bertoša B, Papa L, et al. Helicobacter pylori purine nucleoside phosphorylase shows new distribution patterns of open and closed active site conformations and unusual biochemical features. FEBS J
2018;285:1305–25.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29430816</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Štefanić Z, Mikleušević G, Luić M, et al.. 
Structural characterization of purine nucleoside phosphorylase from human pathogen Helicobacter pylori. Int J Biol Macromol
2017;101:518–26.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28336275</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bzowska A, Magnowska L, Kazimierczuk Z.. 
Synthesis of 6-aryloxy- and 6-arylalkoxy-2-chloropurines and their interactions with purine nucleoside phosphorylase from Escherichia coli. Z Naturforsch C
1999;54:1055–67.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10685497</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jones JW, Robins RK.. 
Purine nucleosides. III. Methylation studies of certain naturally occurring purine nucleosides. J Am Chem Soc
1963;85:193–201.</Citation>
        </Reference>
        <Reference>
          <Citation>Schrader WP, Stacy AR, Pollara B.. 
Purification of human erythrocyte adenosine deaminase by affinity column chromatography. J Biol Chem
1976;251:4026–32.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">932020</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bzowska A, Kazimierczuk Z, Seela F.. 
7-deazapurine 2'-deoxyribofuranosides are noncleavable competitive inhibitors of Escherichia coli purine nucleoside phosphorylase (PNP). Acta Biochim Pol
1998;45:755–68.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9918502</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bzowska A, Kazimierczuk Z.. 
2-Chloro-2'-deoxyadenosine (cladribine) and its analogues are good substrates and potent selective inhibitors of Escherichia coli purine-nucleoside phosphorylase. Eur J Biochem
1995;233:886–90.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8521855</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kalckar HM, Shafran W.. 
Differential spectrophotometry of purine compounds by means of specific enzymes; Determination of hydroxypurine compounds. J Biol Chem
1947;167:429–43.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20285039</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kulikowska E, Bzowska A, Wierzchowski J, Shugar D.. 
Properties of two unusual, and fluorescent, substrates of purine-nucleoside phosphorylase: 7-methylguanosine and 7-methylinosine. Biochim Biophys Acta (BBA)/Protein Struct Mol
1986;874:355–63.</Citation>
        </Reference>
        <Reference>
          <Citation>Bzowska A, Kulikowska E, Shugar D.. 
Properties of purine nucleoside phosphorylase (PNP) of mammalian and bacterial origin. Z Naturforsch C J Biosci
1990;45:59–70.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2109978</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Segel IH, Enzyme kinetics: behavior and analysis of rapid equilibrium and steady-state enzyme systems. Vol. 2. New York, NY: John Wiley Sons; 1993.</Citation>
        </Reference>
        <Reference>
          <Citation>Copeland RA, Enzymes. New York, NY: John Wiley &amp; Sons, Inc.; 2000.</Citation>
        </Reference>
        <Reference>
          <Citation>Irie Y, Tateda K, Matsumoto T, et al.. 
Antibiotic MICs and short time-killing against Helicobacter pylori: therapeutic potential of kanamycin. J Antimicrob Chemother
1997;40:235–40.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9301989</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chowers MY, Keller N, Tal R, et al. Human gastrin: a Helicobacter pylori-specific growth factor. Gastroenterology
1999;117:1113–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10535874</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Knezevic P, Aleksic Sabo V, Simin N, et al. A colorimetric broth microdilution method for assessment of Helicobacter pylori sensitivity to antimicrobial agents. J Pharm Biomed Anal
2018;152:271–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29448222</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Krzyżek P, Franiczek R, Krzyżanowska B, et al.. 
In vitro activity of 3-bromopyruvate, an anticancer compound, against antibiotic-susceptible and antibiotic-resistant Helicobacter pylori strains. Cancers (Basel)
2019;11:229.</Citation>
        </Reference>
        <Reference>
          <Citation>EUCAST . Breakpoint tables for interpretation of MICs and zone diameters. Version 11.0, 2021. Available from: http://www.eucast.org.</Citation>
        </Reference>
        <Reference>
          <Citation>Pillai SK, Eliopoulos GM, Moellering RC. Antimicrobial combinations. Antibiotics in laboratory medicine. Philadelphia, PA: Wolters Kluwer Health; 2005:365–409.</Citation>
        </Reference>
        <Reference>
          <Citation>Kabsch W.
Xds. Acta Crystallogr D Biol Crystallogr
2010;66:125–32.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2815665</ArticleId>
            <ArticleId IdType="pubmed">20124692</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vagin A, Teplyakov A.. 
MOLREP: an automated program for molecular replacement. J Appl Crystallogr
1997;30:1022–5.</Citation>
        </Reference>
        <Reference>
          <Citation>Liebschner D, Afonine PV, Baker ML, Bunkóczi G, et al.. 
Macromolecular structure determination using X-rays, neutrons and electrons: recent developments in phenix. Acta Crystallogr D Struct Biol
2019;75:861–77.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6778852</ArticleId>
            <ArticleId IdType="pubmed">31588918</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schrödinger LLC . The {PyMOL} molecular graphics system, Version∼1.8. 2015.</Citation>
        </Reference>
        <Reference>
          <Citation>Mikleušević G, Štefanić Z, Narczyk M, et al.. 
Validation of the catalytic mechanism of Escherichia coli purine nucleoside phosphorylase by structural and kinetic studies. Biochimie
2011;93:1610–22.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21672603</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Luić M, Štefanić Z.. 
Can crystal symmetry and packing influence the active site conformation of homohexameric purine nucleoside phosphorylases?
Croat Chem Acta
2016;89:197–202.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
